Document Type


Publication Date


Academic Year



Introduction : Continuous positive airway pressure (CPAP) therapy is an established therapy for patients diagnosed with obstructive sleep apnea (OSA). The following study aims to measure the impact of CPAP therapy on lipid and liver profiles of patients diagnosed with OSA. We hypothesize that CPAP therapy will improve patient serum lipid and liver measures in this patient population compared to patient baseline prior to CPAP therapy. Furthermore, we also will examine differences in hepatic ultrasound results for OSA patients on CPAP therapy.

Methods: The target patient population has moderate-severe OSA, defined as an Apnea-Hypopnea Index greater than 15. The intervention is defined as a minimum of four hours of CPAP therapy use nightly on average. For lipid panel outcomes, we recorded high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), total cholesterol (TC), and triglycerides (TG). For liver panel outcomes, we measured aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values. All values were compared to each patients’ averaged baseline values six months prior to initiation of CPAP therapy. Furthermore, we also examined hepatic ultrasound results prior to and after beginning CPAP therapy.

Results: Data collection is currently ongoing. We expect preliminary data of ten chart reviews of eligible subjects show lower HDL, LDL, TC, TG, AST, and ALT on lipid and liver function tests after consistent CPAP use compared to baseline. Unfortunately, due to this initial small pilot sample size, no significant findings with regard to hepatic ultrasound results have been observed.

Discussion: Our results demonstrate that consistent CPAP therapy use helps to lower liver function and lipid tests. This provides support that CPAP therapy, in conjunction with treating OSA, may help to improve outcome values for patients with hypertriglyceridemia and poor liver function. We will continue to collect data on a much larger sample of patients to adequately test our study hypothesis regarding the effects of CPAP therapy effects on hepatic outcomes, such as liver failure, which would provide further support of the beneficial effects of CPAP therapy on vulnerable populations.